Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma

  • By

  • Revadhi C. Chelvarajah

  • Lessandra Y. S. Chee

  • Jie Su

  • Brian O'Sullivan

  • Christopher M. K. L. Yao

  • Enrique Sanz-Garcia

  • Stephen M. Smith

  • Ilan Weinreb

  • Scott Bratman

  • B. C. John Cho

  • Ezra Hahn

  • Andrew Hope

  • Ali Hosni

  • John Kim

  • Andrew McPartlin

  • Nauman Malik

  • Chiaojung Jillian Tsai

  • John de Almeida

  • Anna Spreafico

  • Li Tong

  • Shao Hui Huang

  • John N Waldron

  • March 12, 2026

Share

Clinical Report: Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal HNSCC

Overview

This study evaluates the prevalence and prognostic significance of p16-positive status in non-oropharyngeal mucosal head and neck squamous cell carcinoma (HNSCC).

Background

The role of p16 positivity as a prognostic marker in non-oropharyngeal HNSCC remains unclear, with conflicting evidence regarding its impact on survival outcomes.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • p16-positive status is associated with favorable outcomes in oropharyngeal carcinoma.
  • Inconsistent survival benefits of p16 positivity have been reported in non-oropharyngeal HNSCC, particularly in laryngeal and hypopharyngeal cancers.
  • Some studies indicate worse survival outcomes for p16-positive oral cavity tumors.
  • Variability in HPV detection methodologies complicates the interpretation of p16 positivity in non-oropharyngeal sites.
  • Testing for p16 is performed at the discretion of clinicians.

Clinical Implications

The prognostic value of p16 positivity may differ significantly based on tumor site.

Conclusion

Current inconsistencies in survival outcomes warrant further investigation.

Related Resources & Content

  1. Chelvarajah, J., Head & Neck, 2023 -- Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer
  2. Head and Neck — Safe Omission of Postoperative Neck Irradiation in Selected pN0 Patients With Locally Advanced Oral Cavity Squamous Cell Carcinoma
  3. Head and Neck — Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC)
  4. Head and Neck — Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?
  5. Frontiers in Oncology — Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma
  6. NCCN Head and Neck Cancers guideline (Version 1.2026)
  7. CAP HPV Head and Neck Guideline Update
  8. Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer - Chelvarajah - Head & Neck - Wiley Online Library
  9. Reevaluating Hypopharyngeal Cancer Staging: The Role of HPV Status in Prognosis - ScienceDirect

Original Source(s)

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer

  • by Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz-Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron

  • March 12, 2026

Related Content

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer

Multimodal salvage therapy for locally advanced esophageal cancer recurrence after failed post-ESD surveillance: a case report

Submental Approach Robotic-Assisted Neck Dissection (SARAND) for Minimally Invasive Bilateral Neck Dissection: A Feasibility Cadaver Dissection Study